Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients
کلید واژه ها
خلاصه
تاریخ
آخرین تأیید شده: | 06/30/2020 |
اولین ارسال: | 12/13/2017 |
ثبت نام تخمینی ارسال شد: | 12/17/2017 |
اولین ارسال: | 12/18/2017 |
آخرین بروزرسانی ارسال شده: | 07/06/2020 |
آخرین به روزرسانی ارسال شده: | 07/07/2020 |
تاریخ شروع مطالعه واقعی: | 11/30/2017 |
تاریخ تخمین اولیه اولیه: | 05/31/2022 |
تاریخ برآورد مطالعه: | 06/30/2022 |
شرایط یا بیماری
مداخله / درمان
Drug: Fycompa
فاز
گروههای بازو
بازو | مداخله / درمان |
---|---|
Experimental: Fycompa | Drug: Fycompa Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks. |
معیارهای صلاحیت
سنین واجد شرایط تحصیل | 18 Years به 18 Years |
جنسیت واجد شرایط مطالعه | All |
داوطلبان سالم را می پذیرد | آره |
شاخص | Inclusion Criteria: - Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed within the 3 years prior to participation as having possible, probable, or definite ALS, either sporadic or familial according to modified El Escorial criteria - Age 18-80, able to provide informed consent, and comply with study procedures - Participants must not have started riluzole for at least 30 days, or be on a stable dose of riluzole for at least 30 days, prior to screening (riluzole-naïve participants are permitted in the study) - Slow VC test equal to or greater than 50% of the predicted value Exclusion Criteria: - The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the participant to provide informed consent - Exposure to any experimental agent within 30 days of entry or at any time during the trial or enrollment in another research study within 30 days of or during this trial - Women who are breastfeeding, who are pregnant or are planning to become pregnant - Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal - Hepatic insufficiency or abnormal liver function (AST and/or ALT greater than 3 times the upper limit of the normal range) - Slow VC test less than 50% of the predicted value - ECG finding of QTc prolongation > 450 ms - Patients who had already undergone tracheostomy |
نتیجه
اقدامات اولیه
1. Safety and Tolerability: Incidence and severity of drug-related adverse effects [During study period up to 4 weeks post- study]
اقدامات ثانویه
1. Efficacy: As measured by change in ALSFRS-R score [During study period up to 4 weeks post- study]